DunnGalvin A, Fleischer DM, Campbell DE, et al. - Researchers conducted the study for analyzing food allergy quality of life (FAQL) changes in children following treatment with epicutaneous immunotherapy (EPIT) for peanut allergy (250 μg, daily epicutaneous peanut protein; DBV712 250 μg). During the 12-month double-blind, randomized, controlled PEPITES trial and the initial 12 months of the open-label PEOPLE follow-up study, FAQL was prospectively measured using the FAQLQ parent proxy form (FAQLQ-PF, for children aged ≤ 12 years) and child form (FAQLQ-CF, child rated if aged ≥ 8 years). Data have been analyzed for between-group differences after treatment unblinding. FAQLQ from placebo candidates (-PF: 96; -CF: 47) and treatment group candidates (-PF: 209; -CF: 105) have been analyzed. EPIT treatment in children with a peanut allergy was found to be associated with significant global and domain-specific FAQL improvement (FAQLQ-PF/-CF), largely driven by increases in eliciting dose.